Insight Molecular Diagnostics Inc. — Director's Dealing 2019

Jul 26, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2019-07-17

Reporting Person: GRIFFITH MELINDA (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$2.12	2029-07-16	Common Stock (45000)		Direct

Footnotes

F1: Options shall vest one year from the date of grant on July 17, 2019, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.